166 related articles for article (PubMed ID: 25412388)
41. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment?
Hari DM; Leung AM; Lee JH; Sim MS; Vuong B; Chiu CG; Bilchik AJ
J Am Coll Surg; 2013 Aug; 217(2):181-90. PubMed ID: 23768788
[TBL] [Abstract][Full Text] [Related]
42. Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database.
Daugherty M; Sedaghatpour D; Bratslavsky G; Shapiro O
Can J Urol; 2018 Aug; 25(4):9414-9420. PubMed ID: 30125522
[TBL] [Abstract][Full Text] [Related]
43. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
[TBL] [Abstract][Full Text] [Related]
44. A comparison between the sixth and seventh editions of the UICC/AJCC staging system for nasopharyngeal carcinoma in a Chinese cohort.
Li J; Zou X; Wu YL; Guo JC; Yun JP; Xu M; Feng QS; Chen LZ; Bei JX; Zeng YX; Chen MY
PLoS One; 2014; 9(12):e116261. PubMed ID: 25536307
[TBL] [Abstract][Full Text] [Related]
45. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy.
Iyer RV; Hanlon AL; Pinover WH; Hanks GE
Cancer; 1999 Apr; 85(8):1816-21. PubMed ID: 10223577
[TBL] [Abstract][Full Text] [Related]
46. Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
; Adamo MP; Boten JA; Coyle LM; Cronin KA; Lam CJ; Negoita S; Penberthy L; Stevens JL; Ward KC
Cancer; 2017 Feb; 123(4):697-703. PubMed ID: 27783399
[TBL] [Abstract][Full Text] [Related]
47. A relook at the 8th edition of the AJCC TNM staging system of anaplastic thyroid carcinoma: A SEER-based study.
Xiang J; Wang Z; Sun W; Zhang H
Clin Endocrinol (Oxf); 2021 Apr; 94(4):700-710. PubMed ID: 33368530
[TBL] [Abstract][Full Text] [Related]
48. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.
Choi SY; Chi BH; Lim B; Kyung YS; You D; Jeong IG; Song C; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2020 Feb; 146(2):537-543. PubMed ID: 31915914
[TBL] [Abstract][Full Text] [Related]
49. Predictive value of the UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classification for patients treated with radical prostatectomy.
Herden J; Heidenreich A; Wittekind C; Weissbach L
Cancer Epidemiol; 2018 Oct; 56():126-132. PubMed ID: 30176542
[TBL] [Abstract][Full Text] [Related]
50. Comparison of staging between the old (6th edition) and new (7th edition) TNM classifications in advanced gastric cancer.
Kikuchi S; Futawatari N; Sakuramoto S; Katada N; Yamashita K; Shibata T; Nemoto M; Watanabe M
Anticancer Res; 2011 Jun; 31(6):2361-5. PubMed ID: 21737665
[TBL] [Abstract][Full Text] [Related]
51. Seminal vesicle invasion combined with extraprostatic extension is associated with higher frequency of biochemical recurrence and lymph node metastasis than seminal vesicle invasion alone: Proposal for further pT3 prostate cancer subclassification.
Rehman A; El-Zaatari ZM; Han SH; Shen SS; Ayala AG; Miles B; Divatia MK; Ketcham MS; Chung BM; Rogers JT; Ro JY
Ann Diagn Pathol; 2020 Dec; 49():151611. PubMed ID: 32956915
[TBL] [Abstract][Full Text] [Related]
52. Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
Abdel-Rahman O
Lung Cancer; 2017 Nov; 113():128-133. PubMed ID: 29110839
[TBL] [Abstract][Full Text] [Related]
53. Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma.
Wang H; Lin Z; Li G; Zhang D; Yu D; Lin Q; Wang J; Zhao Y; Pi G; Zhang T
BMC Cancer; 2020 Mar; 20(1):188. PubMed ID: 32138704
[TBL] [Abstract][Full Text] [Related]
54. Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.
Toffalorio F; Radice D; Spaggiari L; Sinno V; Barberis M; Spitaleri G; Giovannini M; Delmonte A; Catania C; Noberasco C; Brambilla D; de Braud F; Veronesi G; Solli P; De Pas T
J Thorac Oncol; 2012 Jul; 7(7):1124-30. PubMed ID: 22610258
[TBL] [Abstract][Full Text] [Related]
55. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
[TBL] [Abstract][Full Text] [Related]
56. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate.
D'Amico AV; Desjardin A; Chen MH; Paik S; Schultz D; Renshaw AA; Loughlin KR; Richie JP
Cancer; 1998 Nov; 83(10):2172-80. PubMed ID: 9827722
[TBL] [Abstract][Full Text] [Related]
57. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
[TBL] [Abstract][Full Text] [Related]
58. Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.
Holmes JA; Wang AZ; Hoffman KE; Hendrix LH; Rosenman JG; Carpenter WR; Godley PA; Chen RC
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):88-94. PubMed ID: 22300560
[TBL] [Abstract][Full Text] [Related]
59. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma.
Shin DW; Lee JC; Kim J; Woo SM; Lee WJ; Han SS; Park SJ; Choi KS; Cha HS; Yoon YS; Han HS; Hong EK; Hwang JH
Eur J Surg Oncol; 2019 Nov; 45(11):2159-2165. PubMed ID: 31202572
[TBL] [Abstract][Full Text] [Related]
60. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
Roach M; Weinberg V; Sandler H; Thompson I
Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
